tiprankstipranks
Trending News
More News >
Hypera SA (HYPMY)
OTHER OTC:HYPMY
Advertisement

Hypera SA (HYPMY) Price & Analysis

Compare
9 Followers

HYPMY Stock Chart & Stats


Hypera SA News

HYPMY FAQ

What was Hypera SA’s price range in the past 12 months?
Hypera SA lowest stock price was $2.75 and its highest was $5.16 in the past 12 months.
    What is Hypera SA’s market cap?
    Hypera SA’s market cap is $2.85B.
      When is Hypera SA’s upcoming earnings report date?
      Hypera SA’s upcoming earnings report date is Oct 28, 2025 which is in 35 days.
        How were Hypera SA’s earnings last quarter?
        Hypera SA released its earnings results on Aug 06, 2025. The company reported $0.119 earnings per share for the quarter, beating the consensus estimate of N/A by $0.119.
          Is Hypera SA overvalued?
          According to Wall Street analysts Hypera SA’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Hypera SA pay dividends?
            Hypera SA pays a Notavailable dividend of $0.053 which represents an annual dividend yield of 0.9%. See more information on Hypera SA dividends here
              What is Hypera SA’s EPS estimate?
              Hypera SA’s EPS estimate for its next earnings report is not yet available.
              How many shares outstanding does Hypera SA have?
              Hypera SA has 633,420,840 shares outstanding.
                What happened to Hypera SA’s price movement after its last earnings report?
                Hypera SA reported an EPS of $0.119 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.509%.
                  Which hedge fund is a major shareholder of Hypera SA?
                  Currently, no hedge funds are holding shares in HYPMY

                  Company Description

                  Hypera SA

                  Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, moon, Lydian, macrodantin, MaxSulid, milgamma, Mioflex – A, nesina, Novotram, oximax, peridal, Peridal Suspension, PredSim, pressaliv, Quadriderm, Rizi, Rizi M, softalm, tacroz, tinodin, umma, and velunid brands. The company also provides dermo-cosmetics products under the Mantecorp Skincare brands; and consumer health products under the Apracur, Benegrip, Coristina d, Engov, Epocler, Estomazil, and other brands. In addition, it offers nutritional and vitamin supplement products under the Tamarine, Vitasay, Biotônico Fontoura, and Zero-Cal brands; and similar and generic medicines under the Neo Química, Sodium Diclofenac, Hydroxyzine, Dipyron, Ibuprofen, Losartan Potassium, Mal Dexchlorpheniramine, Naproxene, Paracetamol, Simethicon, Loratadine, Omeprazole, Tadalaphyl, and Desogestrel brand names. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. is based in São Paulo, Brazil.

                  Hypera SA (HYPMY) Earnings & Revenues

                  HYPMY Company Deck

                  HYPMY Earnings Call

                  Q2 2025
                  0:00 / 0:00
                  Earnings Call Sentiment|Neutral
                  The earnings call presented a mixed picture. On the positive side, Hypera Pharma reported significant sell-out growth, successful product launches, and strong cash flow. The company's sustainability efforts were also recognized. However, these were offset by a decline in net revenue and gross margins due to the working capital optimization strategy. Additionally, there were challenges in the generics market. Overall, the sentiment is balanced, with both positive achievements and significant challenges.View all HYPMY earnings summaries
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Perrigo Company
                  Supernus Pharmaceuticals
                  ANI Pharmaceuticals
                  Indivior
                  Amneal Pharmaceuticals

                  Ownership Overview

                  <0.01%0.03%99.97%
                  Insiders
                  0.03% Other Institutional Investors
                  99.97% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis